5-chloro-4-hydroxyl-2(1H)-pyridone crystal form, preparation method and application thereof

The invention discloses a 5-chloro-4-hydroxyl-2(1H)-pyridone crystal form, a preparation method and application thereof. Intervals of crystal faces d of diffraction peaks in a powder X-ray diffraction diagram of P crystal forms of 5-chloro-4-hydroxyl-2(1H)-pyridone are 5.93, 4.79, 3.46, 3.42, 3.24,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: YAN XIANGPING, WANG PUHAI, CAO YANFENG, ZHU QINGLING, DING YIMEI, LIU YU
Format: Patent
Sprache:chi ; eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator YAN XIANGPING
WANG PUHAI
CAO YANFENG
ZHU QINGLING
DING YIMEI
LIU YU
description The invention discloses a 5-chloro-4-hydroxyl-2(1H)-pyridone crystal form, a preparation method and application thereof. Intervals of crystal faces d of diffraction peaks in a powder X-ray diffraction diagram of P crystal forms of 5-chloro-4-hydroxyl-2(1H)-pyridone are 5.93, 4.79, 3.46, 3.42, 3.24, 2.97 and 2.77; and relative peak strengths corresponding to the diffraction peaks are 59, 27, 100, 35, 61, 16 and 22. An alkali-solution and acid-isolation crystallizing method is adopted in the preparation method of the P crystal forms. The crystal forms can be used as a dihydropyrimidine dehydrogenase inhibitor for preparing a drug for treating cancers. The crystal forms have the advantages of better thermodynamic stability, dissolution and bioavailability. The preparation method is simple and easy and suitable for industrialization application.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN101921227BB</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN101921227BB</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN101921227BB3</originalsourceid><addsrcrecordid>eNqNijEKAjEQANNYiPqHYKVgwERFbO9QrrKyszhCskcOctllk8L8XkEfYDEMDDMXz5NyISKjOqpQPeOrRmU2utsqqjx6TCAd11xslAPytJPEQJZtGTHJCUpAL236QBRH980lAAMOSzEbbMyw-nkh1rfro-0UEPaQyTpIUPr2rvf6YrQx56Y5_DW9AURbOxI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>5-chloro-4-hydroxyl-2(1H)-pyridone crystal form, preparation method and application thereof</title><source>esp@cenet</source><creator>YAN XIANGPING ; WANG PUHAI ; CAO YANFENG ; ZHU QINGLING ; DING YIMEI ; LIU YU</creator><creatorcontrib>YAN XIANGPING ; WANG PUHAI ; CAO YANFENG ; ZHU QINGLING ; DING YIMEI ; LIU YU</creatorcontrib><description>The invention discloses a 5-chloro-4-hydroxyl-2(1H)-pyridone crystal form, a preparation method and application thereof. Intervals of crystal faces d of diffraction peaks in a powder X-ray diffraction diagram of P crystal forms of 5-chloro-4-hydroxyl-2(1H)-pyridone are 5.93, 4.79, 3.46, 3.42, 3.24, 2.97 and 2.77; and relative peak strengths corresponding to the diffraction peaks are 59, 27, 100, 35, 61, 16 and 22. An alkali-solution and acid-isolation crystallizing method is adopted in the preparation method of the P crystal forms. The crystal forms can be used as a dihydropyrimidine dehydrogenase inhibitor for preparing a drug for treating cancers. The crystal forms have the advantages of better thermodynamic stability, dissolution and bioavailability. The preparation method is simple and easy and suitable for industrialization application.</description><language>chi ; eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2012</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20120905&amp;DB=EPODOC&amp;CC=CN&amp;NR=101921227B$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20120905&amp;DB=EPODOC&amp;CC=CN&amp;NR=101921227B$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>YAN XIANGPING</creatorcontrib><creatorcontrib>WANG PUHAI</creatorcontrib><creatorcontrib>CAO YANFENG</creatorcontrib><creatorcontrib>ZHU QINGLING</creatorcontrib><creatorcontrib>DING YIMEI</creatorcontrib><creatorcontrib>LIU YU</creatorcontrib><title>5-chloro-4-hydroxyl-2(1H)-pyridone crystal form, preparation method and application thereof</title><description>The invention discloses a 5-chloro-4-hydroxyl-2(1H)-pyridone crystal form, a preparation method and application thereof. Intervals of crystal faces d of diffraction peaks in a powder X-ray diffraction diagram of P crystal forms of 5-chloro-4-hydroxyl-2(1H)-pyridone are 5.93, 4.79, 3.46, 3.42, 3.24, 2.97 and 2.77; and relative peak strengths corresponding to the diffraction peaks are 59, 27, 100, 35, 61, 16 and 22. An alkali-solution and acid-isolation crystallizing method is adopted in the preparation method of the P crystal forms. The crystal forms can be used as a dihydropyrimidine dehydrogenase inhibitor for preparing a drug for treating cancers. The crystal forms have the advantages of better thermodynamic stability, dissolution and bioavailability. The preparation method is simple and easy and suitable for industrialization application.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2012</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNijEKAjEQANNYiPqHYKVgwERFbO9QrrKyszhCskcOctllk8L8XkEfYDEMDDMXz5NyISKjOqpQPeOrRmU2utsqqjx6TCAd11xslAPytJPEQJZtGTHJCUpAL236QBRH980lAAMOSzEbbMyw-nkh1rfro-0UEPaQyTpIUPr2rvf6YrQx56Y5_DW9AURbOxI</recordid><startdate>20120905</startdate><enddate>20120905</enddate><creator>YAN XIANGPING</creator><creator>WANG PUHAI</creator><creator>CAO YANFENG</creator><creator>ZHU QINGLING</creator><creator>DING YIMEI</creator><creator>LIU YU</creator><scope>EVB</scope></search><sort><creationdate>20120905</creationdate><title>5-chloro-4-hydroxyl-2(1H)-pyridone crystal form, preparation method and application thereof</title><author>YAN XIANGPING ; WANG PUHAI ; CAO YANFENG ; ZHU QINGLING ; DING YIMEI ; LIU YU</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN101921227BB3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2012</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>YAN XIANGPING</creatorcontrib><creatorcontrib>WANG PUHAI</creatorcontrib><creatorcontrib>CAO YANFENG</creatorcontrib><creatorcontrib>ZHU QINGLING</creatorcontrib><creatorcontrib>DING YIMEI</creatorcontrib><creatorcontrib>LIU YU</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>YAN XIANGPING</au><au>WANG PUHAI</au><au>CAO YANFENG</au><au>ZHU QINGLING</au><au>DING YIMEI</au><au>LIU YU</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>5-chloro-4-hydroxyl-2(1H)-pyridone crystal form, preparation method and application thereof</title><date>2012-09-05</date><risdate>2012</risdate><abstract>The invention discloses a 5-chloro-4-hydroxyl-2(1H)-pyridone crystal form, a preparation method and application thereof. Intervals of crystal faces d of diffraction peaks in a powder X-ray diffraction diagram of P crystal forms of 5-chloro-4-hydroxyl-2(1H)-pyridone are 5.93, 4.79, 3.46, 3.42, 3.24, 2.97 and 2.77; and relative peak strengths corresponding to the diffraction peaks are 59, 27, 100, 35, 61, 16 and 22. An alkali-solution and acid-isolation crystallizing method is adopted in the preparation method of the P crystal forms. The crystal forms can be used as a dihydropyrimidine dehydrogenase inhibitor for preparing a drug for treating cancers. The crystal forms have the advantages of better thermodynamic stability, dissolution and bioavailability. The preparation method is simple and easy and suitable for industrialization application.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language chi ; eng
recordid cdi_epo_espacenet_CN101921227BB
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title 5-chloro-4-hydroxyl-2(1H)-pyridone crystal form, preparation method and application thereof
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T23%3A58%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=YAN%20XIANGPING&rft.date=2012-09-05&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN101921227BB%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true